most effective glp-1 medication 2025 Market Overview: Agonists and the Obesity Market | Blog GLP-1 Users: Trends on Long-Term

While Retatrutide has shown fewer gastrointestinal issues, it still comes with potential side effects

The SUMMIT study assesses tirzepatides impact on HF with HFpEF in obese patients

Moreover, Aib significantly promotes the formation of alpha helices within the peptide structure, which enhances the molecules enzymatic stability and potency without significantly altering the structural integrity of the native peptide [16]

Patients are becoming more aware of innovative treatments for both diabetes and obesity, boosting demand

Tirzepatide, without glucagon agonism, does not carry that specific signal

Suitable regulatory frameworks and new product launches also contribute to market growth